EYPT - EyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead Program
2024-05-07 12:50:20 ET
Summary
- Despite NPDR primary endpoint miss, potential exists with EyePoint Pharmaceuticals releasing 12-month phase 2 PAVIA data; potential for continued advancement depending upon data.
- LUGANO and LUCIA are two pivotal phase 3 studies expected to be initiated in the 2nd half of 2024, which are going to use DURAVYU for Wet-AMD treatment.
- The global macular degeneration market is estimated to reach $23.29 billion by 2029.
- It is expected that final results from the phase 2 VERONA trial, using DURAVYU for the treatment of patients with Diabetic Macular Edema, are expected in Q1 of 2025.
EyePoint Pharmaceuticals, Inc. ( EYPT ) just reported results the other day from its phase 2 PAVIA trial, which used its drug DURAVYU for the treatment of patients with non-proliferative diabetic retinopathy [NPDR]. The primary endpoint of this study failed to achieve statistical significance, causing the stock price to trade lower by as much as 43% in one day, trading down to $11.20 per share....
EyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead Program